Denmark
# |
Name |
Net Cash Used Provided By Financing Activities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 148.22 M
|
Dec. 31, 2023 | USD 130.66 | 2.64% |
|
Denmark |
|
2 |
USD 134.26 M
|
Dec. 31, 2023 | USD 102.45 | 7.03% |
|
Denmark |
|
3 |
USD 108.92 M
|
Dec. 31, 2023 | USD 24.06 | 1.57% |
|
Denmark |
|
4 |
USD 10.69 M
|
Dec. 31, 2023 | USD 2.46 | -0.40% |
|
Denmark |
|
5 |
USD 4.72 M
|
Dec. 31, 2023 | USD 2.73 | 4.48% |
|
Denmark |
|
6 |
USD -9.35 B
|
Dec. 31, 2023 | USD 86.17 | 4.52% |
|
Denmark |
The Vaccines company in Denmark with the highest Net Cash Used Provided By Financing Activities is Ascendis Pharma A/S (NasdaqGS: ASND) at USD 148.22 M.
The Vaccines company in Denmark with the lowest Net Cash Used Provided By Financing Activities is Novo Nordisk A/S (Copenhagen Stock Exchange: NOVO-B.CO) at USD -9.35 B.
The top 10 Vaccines companies in Denmark by Net Cash Used Provided By Financing Activities are Ascendis Pharma A/S, Zealand Pharma A/S, Bavarian Nordic A/S, Evaxion Biotech A/S, ExpreS2ion Biotech Holding AB (publ) and Novo Nordisk A/S.
The bottom 10 Vaccines companies in Denmark by Net Cash Used Provided By Financing Activities are Novo Nordisk A/S, ExpreS2ion Biotech Holding AB (publ), Evaxion Biotech A/S, Bavarian Nordic A/S, Zealand Pharma A/S and Ascendis Pharma A/S.